160 related articles for article (PubMed ID: 26976870)
1. Effect of Surotomycin, a Novel Cyclic Lipopeptide Antibiotic, on Intestinal Colonization with Vancomycin-Resistant Enterococci and Klebsiella pneumoniae in Mice.
Deshpande A; Hurless K; Cadnum JL; Chesnel L; Gao L; Chan L; Kundrapu S; Polinkovsky A; Donskey CJ
Antimicrob Agents Chemother; 2016 Jun; 60(6):3333-9. PubMed ID: 26976870
[TBL] [Abstract][Full Text] [Related]
2. Effect of Fidaxomicin versus Vancomycin on Susceptibility to Intestinal Colonization with Vancomycin-Resistant Enterococci and Klebsiella pneumoniae in Mice.
Deshpande A; Hurless K; Cadnum JL; Chesnel L; Gao L; Chan L; Kundrapu S; Polinkovsky A; Donskey CJ
Antimicrob Agents Chemother; 2016 Jul; 60(7):3988-93. PubMed ID: 27090175
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of oral ramoplanin for inhibition of intestinal colonization by vancomycin-resistant enterococci in mice.
Stiefel U; Pultz NJ; Helfand MS; Donskey CJ
Antimicrob Agents Chemother; 2004 Jun; 48(6):2144-8. PubMed ID: 15155213
[TBL] [Abstract][Full Text] [Related]
4. Surotomycin demonstrates low in vitro frequency of resistance and rapid bactericidal activity in Clostridium difficile, Enterococcus faecalis, and Enterococcus faecium.
Mascio CT; Chesnel L; Thorne G; Silverman JA
Antimicrob Agents Chemother; 2014 Jul; 58(7):3976-82. PubMed ID: 24798273
[TBL] [Abstract][Full Text] [Related]
5. Enteric microbiome profiles during a randomized Phase 2 clinical trial of surotomycin versus vancomycin for the treatment of Clostridium difficile infection.
Cannon K; Byrne B; Happe J; Wu K; Ward L; Chesnel L; Louie T
J Antimicrob Chemother; 2017 Dec; 72(12):3453-3461. PubMed ID: 28927227
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the Effects of Surotomycin Treatment on Clostridium difficile Toxin A and B Production, Immune Response, and Morphological Changes.
Endres BT; Bassères E; Khaleduzzaman M; Alam MJ; Chesnel L; Garey KW
Antimicrob Agents Chemother; 2016 Jun; 60(6):3519-23. PubMed ID: 27021314
[TBL] [Abstract][Full Text] [Related]
7. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease.
Al-Nassir WN; Sethi AK; Li Y; Pultz MJ; Riggs MM; Donskey CJ
Antimicrob Agents Chemother; 2008 Jul; 52(7):2403-6. PubMed ID: 18443120
[TBL] [Abstract][Full Text] [Related]
8. Sub-lethal doses of surotomycin and vancomycin have similar effects on Clostridium difficile virulence factor production in vitro.
Aldape MJ; Rice SN; Field KP; Bryant AE; Stevens DL
J Med Microbiol; 2018 Dec; 67(12):1689-1697. PubMed ID: 30307842
[TBL] [Abstract][Full Text] [Related]
9. Mutations associated with reduced surotomycin susceptibility in Clostridium difficile and Enterococcus species.
Adams HM; Li X; Mascio C; Chesnel L; Palmer KL
Antimicrob Agents Chemother; 2015 Jul; 59(7):4139-47. PubMed ID: 25941217
[TBL] [Abstract][Full Text] [Related]
10. Tapering Courses of Oral Vancomycin Induce Persistent Disruption of the Microbiota That Provide Colonization Resistance to Clostridium difficile and Vancomycin-Resistant Enterococci in Mice.
Tomas ME; Mana TSC; Wilson BM; Nerandzic MM; Joussef-Piña S; Quiñones-Mateu ME; Donskey CJ
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29530853
[TBL] [Abstract][Full Text] [Related]
11. Analysis of Clostridium difficile biofilms: imaging and antimicrobial treatment.
James GA; Chesnel L; Boegli L; deLancey Pulcini E; Fisher S; Stewart PS
J Antimicrob Chemother; 2018 Jan; 73(1):102-108. PubMed ID: 29029221
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of surotomycin against contemporary clinical isolates of toxigenic Clostridium difficile strains obtained in Spain.
Reigadas E; Alcalá L; Marín M; Pelaéz T; Martin A; Iglesias C; Bouza E
J Antimicrob Chemother; 2015 Aug; 70(8):2311-5. PubMed ID: 25876881
[TBL] [Abstract][Full Text] [Related]
13. Distinct but Spatially Overlapping Intestinal Niches for Vancomycin-Resistant Enterococcus faecium and Carbapenem-Resistant Klebsiella pneumoniae.
Caballero S; Carter R; Ke X; Sušac B; Leiner IM; Kim GJ; Miller L; Ling L; Manova K; Pamer EG
PLoS Pathog; 2015 Sep; 11(9):e1005132. PubMed ID: 26334306
[TBL] [Abstract][Full Text] [Related]
14. Activity of a novel cyclic lipopeptide, CB-183,315, against resistant Clostridium difficile and other Gram-positive aerobic and anaerobic intestinal pathogens.
Snydman DR; Jacobus NV; McDermott LA
Antimicrob Agents Chemother; 2012 Jun; 56(6):3448-52. PubMed ID: 22391542
[TBL] [Abstract][Full Text] [Related]
15. Impact of Surotomycin on the Gut Microbiota of Healthy Volunteers in a Phase 1 Clinical Trial.
Citron DM; Tyrrell KL; Dale SE; Chesnel L; Goldstein EJ
Antimicrob Agents Chemother; 2016 Apr; 60(4):2069-74. PubMed ID: 26787687
[TBL] [Abstract][Full Text] [Related]
16. Cadazolid Does Not Promote Intestinal Colonization of Vancomycin-Resistant Enterococci in Mice.
Seiler P; Enderlin-Paput M; Pfaff P; Weiss M; Ritz D; Clozel M; Locher HH
Antimicrob Agents Chemother; 2016 Jan; 60(1):628-31. PubMed ID: 26503650
[TBL] [Abstract][Full Text] [Related]
17. In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species.
Citron DM; Tyrrell KL; Merriam CV; Goldstein EJ
Antimicrob Agents Chemother; 2012 Mar; 56(3):1613-5. PubMed ID: 22183166
[TBL] [Abstract][Full Text] [Related]
18. Lack of increased colonization with vancomycin-resistant enterococci during preferential use of vancomycin for treatment during an outbreak of healthcare-associated Clostridium difficile infection.
Miller M; Bernard L; Thompson M; Grima D; Pepin J
Infect Control Hosp Epidemiol; 2010 Jul; 31(7):710-5. PubMed ID: 20518636
[TBL] [Abstract][Full Text] [Related]
19. Antianaerobic antibiotic therapy promotes overgrowth of antibiotic-resistant, gram-negative bacilli and vancomycin-resistant enterococci in the stool of colonized patients.
Bhalla A; Pultz NJ; Ray AJ; Hoyen CK; Eckstein EC; Donskey CJ
Infect Control Hosp Epidemiol; 2003 Sep; 24(9):644-9. PubMed ID: 14510245
[TBL] [Abstract][Full Text] [Related]
20. Surotomycin versus vancomycin for Clostridium difficile infection: Phase 2, randomized, controlled, double-blind, non-inferiority, multicentre trial.
Lee CH; Patino H; Stevens C; Rege S; Chesnel L; Louie T; Mullane KM
J Antimicrob Chemother; 2016 Oct; 71(10):2964-71. PubMed ID: 27432604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
